content: UNITED STATES
                         SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): June 18, 2003
                                                             -------------
  
  
                                 CYTOGEN CORPORATION
                                 -------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
             Delaware                     000-14879                 222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction    (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  
  650 College Road East, Suite 3100, Princeton, NJ                        08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
  
  
                                   (609) 750-8200
                     ------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
  
  
        --------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  <PAGE>
  
  
           Item 5.   Other Events and Required FD Disclosure.
  
  On June 18, 2003,  Advanced Magnetics,  Inc. ("Advanced  Magnetics") and Cytogen
  Corporation ("Cytogen") announced in a press release the publication of clinical
  data in the New England  Journal of Medicine  showing  that  magnetic  resonance
  imaging  with  Combidex(R),   Advanced  Magnetic's  investigational  iron  oxide
  nanoparticle used to aid in the diagnosis of lymph node disease,  allows for the
  noninvasive  assessment of lymph nodes in patients with prostate cancer. Cytogen
  has a  license  with  Advanced  Magnetics  for  exclusive  marketing  rights  to
  Combidex(R) in the United States.
  
  Such press release is attached hereto as Exhibit 99.1 and is incorporated herein
  by reference.  The foregoing  description  of such press release is qualified in
  its entirety by reference to such document.
  
           Item 7.   Financial Statements, Pro Forma Financial Information and
                     Exhibits.
  
           (c) Exhibits.
  
                 Exhibit No.       Description
                 -----------       -----------
  
                     99.1          Press release dated June 18, 2003
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  
                                     Cytogen Corporation
  
  
  
                                     By: /s/ Michael D. Becker
                                         ----------------------------------------
                                          Michael D. Becker,
                                          President and Chief Executive Officer
  
  
  Date:  July 3, 2003
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form_8k061803.txt", "description": "FORM 8-K DATED JUNE 18, 2003", "secsgml_size_bytes": 3430}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03775179"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
                         SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): June 18, 2003
                                                             -------------
  
                                 CYTOGEN CORPORATION
                                 -------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction    (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, Suite 3100, Princeton, NJ                        08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
                                   (609) 750-8200
                     ------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
        --------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  Item 5.   Other Events and Required FD Disclosure.
  
  On June 18, 2003,  Advanced Magnetics,  Inc. ("Advanced  Magnetics") and Cytogen
  Corporation ("Cytogen") announced in a press release the publication of clinical
  data in the New England  Journal of Medicine  showing  that  magnetic  resonance
  imaging  with  Combidex(R),   Advanced  Magnetic's  investigational  iron  oxide
  nanoparticle used to aid in the diagnosis of lymph node disease,  allows for the
  noninvasive  assessment of lymph nodes in patients with prostate cancer. Cytogen
  has a  license  with  Advanced  Magnetics  for  exclusive  marketing  rights  to
  Combidex(R) in the United States.
  
  Such press release is attached hereto as Exhibit 99.1 and is incorporated herein
  by reference.  The foregoing  description  of such press release is qualified in
  its entirety by reference to such document.
  
           Item 7.   Financial Statements, Pro Forma Financial Information and
                     Exhibits.
  
           (c) Exhibits.
  
                 Exhibit No.       Description
                 -----------       -----------
  
                     99.1          Press release dated June 18, 2003
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                     Cytogen Corporation
  
                                     By: /s/ Michael D. Becker
                                         ----------------------------------------
                                          Michael D. Becker,
                                          President and Chief Executive Officer
  
  Date:  July 3, 2003